Fig. 2: RFS and DMFS. | Nature Medicine

Fig. 2: RFS and DMFS.

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Fig. 2

a, Kaplan–Meier estimates of RFS defined as the time between randomization and the first date of documented recurrence (local, regional or distant recurrence or new primary melanomas (excluding in situ)) or death due to any cause in all randomized patients. b, DMFS defined as the time between randomization and first distant metastasis or death due to any cause in a subset of intention-to-treat patients, defined as those with resected stage III−IVA−IVB melanoma (those without presence of baseline metastasis prior to surgical resection—that is, stage III cutaneous and stage IVA−IVB mucosal melanoma). RFS statistical analysis was two-sided log-rank test, with no multiple comparisons. Symbols (circles) indicate censored data. Dashed lines indicate landmark analyses. CI, confidence interval; HR, hazard ratio; mDMFS, median DMFS; mRFS, median RFS; mo, months; NIVO, nivolumab; NR, not reached; RELA, relatlimab.

Back to article page